Market Cap
US$1.8b
Last Updated
2019/09/22 00:17 UTC
Data Sources
Company Financials +
Executive Summary
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States.
Snowflake
Fundamentals
Excellent balance sheet with high growth potential.
Similar Companies
Share Price & News
How has Zogenix's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-0.5%
ZGNX
1.2%
US Pharmaceuticals
-0.6%
US Market
1 Year Return
-15.7%
ZGNX
-8.4%
US Pharmaceuticals
0.7%
US Market
ZGNX underperformed the Pharmaceuticals industry which returned -8.4% over the past year.
ZGNX underperformed the Market in United States of America which returned 0.6% over the past year.
Share holder returns
| ZGNX | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.5% | 1.2% | -0.6% |
| 30 Day | -17.2% | 1.8% | 2.9% |
| 90 Day | 1.6% | -4.3% | 1.3% |
| 1 Year | -15.7%-15.7% | -6.2%-8.4% | 2.9%0.7% |
| 3 Year | 296.5%296.5% | 12.6%4.7% | 44.6%35.2% |
| 5 Year | 338.9%338.9% | 22.9%9.8% | 61.9%44.2% |
Price Volatility Vs. Market
How volatile is Zogenix's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
We're Excited To See How Zogenix (NASDAQ:ZGNX) Uses Its Cash Hoard To Grow3 weeks ago | Simply Wall St
Have Insiders Been Selling Zogenix, Inc. (NASDAQ:ZGNX) Shares?1 month ago | Simply Wall St
Analysts Expect Breakeven For Zogenix, Inc. (NASDAQ:ZGNX)Valuation
Is Zogenix undervalued based on future cash flows and its price relative to the stock market?
>50%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Zogenix's share price is below the future cash flow value, and at a moderate discount (> 20%).
Zogenix's share price is below the future cash flow value, and at a substantial discount (> 40%).
Price Based on Earnings
Zogenix is loss making, we can't compare its value to the US Pharmaceuticals industry average.
Zogenix is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Zogenix, we can't assess if its growth is good value.
Price Based on Value of Assets
Zogenix is overvalued based on assets compared to the US Pharmaceuticals industry average.
Next Steps
Future Growth
How is Zogenix expected to perform in the next 1 to 3 years based on estimates from 10 analysts?
69.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Zogenix's revenue is expected to grow significantly at over 20% yearly.
Zogenix's earnings are expected to grow significantly at over 20% yearly.
Zogenix's revenue growth is expected to exceed the United States of America market average.
Zogenix's earnings growth is expected to exceed the United States of America market average.
Zogenix's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Zogenix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Zogenix performed over the past 5 years?
-49.3%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Zogenix does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Zogenix's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Zogenix's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Zogenix has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Zogenix has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Zogenix improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Zogenix's financial position?
Financial Position Analysis
Zogenix is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Zogenix's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Zogenix has no debt.
Zogenix has no debt compared to 5 years ago when it was 3.4%.
Balance Sheet
Low level of unsold assets.
Zogenix has no debt, it does not need to be covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Zogenix has sufficient cash runway for more than 3 years based on current free cash flow.
Unable to confirm if Zogenix has at least 1 year of cash runway based on growing free cash flows without relevant data.
Next Steps
Dividend
What is Zogenix's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Zogenix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Zogenix's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Zogenix has not reported any payouts.
Unable to verify if Zogenix's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Zogenix has not reported any payouts.
Future Payout to Shareholders
No need to calculate the sustainability of Zogenix's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of Zogenix's salary, the management and board of directors tenure and is there insider trading?
5.8yrs
Average management tenure
CEO
Steve Farr (60yo)
4.4yrs
Tenure
US$6,650,252
Compensation
Dr. Stephen J. Farr, also known as Steve, Ph.D., co-founded Zogenix, Inc. in 2006 and has been its President since May 2006 and its Chief Executive Officer since April 2015. Dr. Farr served as the Chief Op ...
CEO Compensation Analysis
Steve's remuneration is higher than average for companies of similar size in United States of America.
Steve's compensation has increased whilst company is loss making.
Management Age and Tenure
5.8yrs
Average Tenure
56yo
Average Age
The average tenure for the Zogenix management team is over 5 years, this suggests they are a seasoned and experienced team.
Board Age and Tenure
11.3yrs
Average Tenure
61.5yo
Average Age
The average tenure for the Zogenix board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Insider Trading
No 3 month open market individual insider trading information.
Recent Insider Transactions
| Entity | Individual |
| Shares | 60,000 |
| Max Price | US$53.10 |
| Entity | Individual |
| Shares | 20,000 |
| Max Price | US$41.35 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 1,468 |
| Max Price | US$42.08 |
Ownership Breakdown
Management Team
Steve Farr (60yo)
Co-Founder
- Tenure: 4.4yrs
- Compensation: US$6.65m
Bret Megargel (50yo)
Vice President of Corporate Development
- Tenure: 13.1yrs
John Turanin (61yo)
VP & GM of Zogenix Technologies
- Tenure: 13.3yrs
- Compensation: US$326.24k
Mike Smith (51yo)
Executive VP
- Tenure: 2.7yrs
- Compensation: US$1.99m
Bradley Galer (57yo)
Executive VP & Chief Medical Officer
- Tenure: 5.8yrs
- Compensation: US$2.55m
Stephen Jenner (51yo)
Vice President of Marketing
- Tenure: 8.7yrs
Gail Farfel (55yo)
Executive VP & Chief Development Officer
- Tenure: 4.2yrs
- Compensation: US$2.36m
Jeff Durflinger (58yo)
Vice President of Technical Operations & Product Supply
- Tenure: 8.5yrs
Catherine O'Connor
Senior Director of Corporate Communications
- Tenure: 0yrs
Ashish Sagrolikar
Executive VP & Chief Commercial Officer
- Tenure: 1.2yrs
- Compensation: US$4.35m
Board Members
Lou Bock (54yo)
Independent Director
- Tenure: 13.1yrs
- Compensation: US$477.90k
Cam Garner (71yo)
Co-founder & Chairman
- Tenure: 13.1yrs
- Compensation: US$517.90k
Steve Farr (60yo)
Co-Founder
- Tenure: 4.4yrs
- Compensation: US$6.65m
Erle Mast (57yo)
Independent Director
- Tenure: 11.3yrs
- Compensation: US$487.90k
Jim Breitmeyer (65yo)
Director
- Tenure: 5.5yrs
- Compensation: US$465.40k
Mark Wiggins (63yo)
Independent Director
- Tenure: 8.3yrs
- Compensation: US$475.40k
David Brushwood
Member of External Safe Use Board
- Tenure: 5.2yrs
Jeff Gudin
Chairperson of External Safe Use Board
- Tenure: 0yrs
John Burke
Member of External Safe Use Board
- Tenure: 0yrs
Debra Gordon
Member of External Safe Use Board
- Tenure: 0yrs
Company Information
Zogenix, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Zogenix, Inc.
- Ticker: ZGNX
- Exchange: NasdaqGM
- Founded: 2006
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.833b
- Shares outstanding: 44.25m
- Website: https://www.zogenix.com
Number of Employees
Location
- Zogenix, Inc.
- 5858 Horton Street
- Suite 455
- Emeryville
- California
- 94608
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ZGNX | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Nov 2010 |
| Z081 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Nov 2010 |
| 0M3O | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Nov 2010 |
Biography
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the FÂ ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/22 00:17 |
| End of Day Share Price | 2019/09/20 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.